- Home
- USAU vs PROK Comparison
USAU vs PROK Comparison
Compare USAU & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USAU | PROK |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.5M | 331.2M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | USAU | PROK |
|---|---|---|
| Price | $14.14 | $1.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $22.83 | $7.40 |
| AVG Volume (30 Days) | 270.3K | ★ 633.3K |
| Earning Date | 03-16-2026 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,402,000.00 | $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $7.38 | $0.46 |
| 52 Week High | $23.72 | $7.13 |
Technical Indicators
Market Signals| Indicator | USAU | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 34.76 | 27.38 |
| Support Level | $12.06 | $0.54 |
| Resistance Level | $14.39 | $2.58 |
| Average True Range (ATR) | 0.85 | 0.14 |
| MACD | -0.29 | -0.07 |
| Stochastic Oscillator | 10.14 | 0.00 |
Price Performance
Historical ComparisonAbout USAU U.S. Gold Corp.
U.S. Gold Corp is an exploration and development company that owns certain mining leases and other mineral rights comprising the CK Gold Project in Wyoming, the Keystone Project in Nevada, and the Challis Gold Project in Idaho.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.